Meeder Asset Management Inc. trimmed its position in shares of Catalent Inc (NYSE:CTLT) by 15.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,118 shares of the company’s stock after selling 3,048 shares during the period. Meeder Asset Management Inc.’s holdings in Catalent were worth $780,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in the company. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new stake in Catalent in the 2nd quarter valued at $145,000. Moneta Group Investment Advisors LLC increased its holdings in Catalent by 105.0% in the 2nd quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock valued at $147,000 after acquiring an additional 1,800 shares during the last quarter. Hartford Investment Management Co. bought a new stake in Catalent in the 2nd quarter valued at $220,000. Rehmann Capital Advisory Group increased its holdings in Catalent by 1,895.9% in the 2nd quarter. Rehmann Capital Advisory Group now owns 5,309 shares of the company’s stock valued at $222,000 after acquiring an additional 5,043 shares during the last quarter. Finally, Chicago Equity Partners LLC bought a new stake in Catalent in the 3rd quarter valued at $237,000. Hedge funds and other institutional investors own 92.08% of the company’s stock.
In related news, insider John R. Chiminski sold 130,545 shares of Catalent stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $45.32, for a total transaction of $5,916,299.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Lance Miyamoto sold 6,525 shares of Catalent stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total transaction of $277,312.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 184,335 shares of company stock worth $8,161,727. Insiders own 1.40% of the company’s stock.
Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 6th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.04. Catalent had a net margin of 2.65% and a return on equity of 19.13%. The firm had revenue of $551.80 million for the quarter, compared to the consensus estimate of $582.44 million. During the same period in the previous year, the firm posted $0.21 EPS. The business’s quarterly revenue was up 1.5% on a year-over-year basis. On average, equities analysts forecast that Catalent Inc will post 1.72 earnings per share for the current fiscal year.
A number of brokerages have issued reports on CTLT. Zacks Investment Research upgraded shares of Catalent from a “sell” rating to a “hold” rating in a report on Monday, October 1st. UBS Group started coverage on shares of Catalent in a report on Tuesday, October 9th. They issued a “neutral” rating and a $48.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on shares of Catalent from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Wednesday, August 29th. Royal Bank of Canada set a $44.00 target price on shares of Catalent and gave the stock a “buy” rating in a report on Wednesday. Finally, TheStreet downgraded shares of Catalent from a “b-” rating to a “c+” rating in a report on Wednesday. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Catalent presently has an average rating of “Buy” and an average target price of $48.11.
TRADEMARK VIOLATION WARNING: This news story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://sportsperspectives.com/2018/11/10/catalent-inc-ctlt-stake-lowered-by-meeder-asset-management-inc.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: Should I invest in “strong buy” stocks?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.